SCHEMBL4907998

SCHEMBL4907998

Cc1ccccc1-c1noc(Cl)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.66
SMN1; SMN2 Q16637 7/20 0.66
RAB9A P51151 7/20 0.66
MEN1 O00255 1/20 0.66
CYP1A2 P05177 1/20 0.66
CYP2C19 P33261 1/20 0.66
KMT2A Q03164 1/20 0.66
GAA P10253 3/20 0.60
MAPK1 P28482 3/20 0.59
TDP1 Q9NUW8 1/20 0.59
MAPT P10636 4/20 0.57
PKM P14618 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
NFKB1 P19838 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
HSD17B10 Q99714 1/20 0.57
NR1H4 Q96RI1 3/20 0.54
TP53 P04637 4/20 0.50
RXFP1 Q9HBX9 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12660084 0.82 NPC1 (0.62) NPC1SMN1; SMN2RAB9AMEN1CYP1A2
SCHEMBL23911673 0.80 SMN1; SMN2 (0.53) NPC1SMN1; SMN2RAB9AMEN1CYP1A2
SCHEMBL1544710 0.79 SMN1; SMN2 (0.55) NPC1SMN1; SMN2RAB9AMEN1CYP1A2
SCHEMBL8016715 0.78 RAB9A (0.53) NPC1SMN1; SMN2RAB9AMEN1CYP1A2
SCHEMBL9028248 0.77 NPC1 (0.56) NPC1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL15479735 0.77 HTT (0.57) NPC1SMN1; SMN2RAB9AMEN1CYP1A2
SCHEMBL14818742 0.77 MAPT (0.58) NPC1SMN1; SMN2RAB9AMEN1CYP1A2
SCHEMBL21485722 0.75 NPC1 (0.77) NPC1SMN1; SMN2RAB9AMEN1CYP1A2
SCHEMBL28869647 0.75 SMN1; SMN2 (0.54) NPC1SMN1; SMN2RAB9AMEN1CYP1A2
SCHEMBL13930879 0.75 RAB9A (1.00) NPC1SMN1; SMN2RAB9AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties PC, GOT2, SDHA NPC1 965/4885SMN1; SMN2 3741/4885RAB9A 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.